State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases Center of Advanced Pharmaceuticals and Biomaterials , China Pharmaceutical University , No. 24 Tongjiaxiang , Nanjing 210009 , China.
Mol Pharm. 2019 Jul 1;16(7):3109-3120. doi: 10.1021/acs.molpharmaceut.9b00342. Epub 2019 May 28.
Given the multiple interactions between neutrophils (NEs) and atherosclerosis (AS), in this study, we exploited NEs as cellular vehicles loaded with cationic liposomes for actively targeting atherosclerotic sites. The cellular vehicles based on NEs possess efficient internalization of cationic liposomes and sensitive response to the chemotaxis of atherosclerotic inflammatory cells, which ultimately realize the targeted delivery of the cargos into the target cells in vitro. Moreover, these effects also translated to significant enhancement of the accumulation of NEs' cargos into the atherosclerotic plaque in vivo after administering NE vehicles to the AS animal model. Consequently, cellular vehicles based on NEs could be a novel strategy for targeted delivery of payloads into atherosclerotic plaque, which would facilitate theranostics for AS and the development of anti-AS drugs to manage the disease.
鉴于中性粒细胞（NE）与动脉粥样硬化（AS）之间的多种相互作用，在本研究中，我们利用 NE 作为细胞载体，装载阳离子脂质体，主动靶向动脉粥样硬化部位。基于 NE 的细胞载体具有高效内化阳离子脂质体的能力，并对动脉粥样硬化炎症细胞的趋化作用敏感，这最终实现了在体外将货物靶向递送至靶细胞。此外，在将 NE 载体施用于 AS 动物模型后，这些作用也显著增强了 NE 载体的货物在动脉粥样硬化斑块中的积累。因此，基于 NE 的细胞载体可能是一种将有效载荷靶向递送至动脉粥样硬化斑块的新策略，这将有助于 AS 的治疗和抗 AS 药物的开发，以管理该疾病。
